#USA #San Francisco #Hagens Berman #Aardvark Therapeutics #AARD

Aardvark Therapeutics Under Legal Scrutiny

Aardvark Therapeutics, listed under the ticker AARD, is currently at the center of a securities fraud class action lawsuit initiated by concerned investors. The firm Hagens Berman Sobol Shapiro LLP has taken the lead in notifying investors about this ongoing case, which emphasizes the importance of transparency and accountability in the biopharmaceutical industry.

Background of the Case

The lawsuit specifically addresses allegations surrounding Aardvark’s development of its drug ARD-101, designed to target bitter taste receptors for treating hyperphagia, primarily in patients suffering from Prader-Willi Syndrome (PWS). The complaint claims that the company made materially false statements and neglected to disclose essential safety information about ARD-101. Investors who purchased shares between the company’s initial public offering (IPO) on February 13, 2025, and May 14, 2026, are particularly implicated in this class action suit.

Key Allegations

Among the primary claims highlighted in the lawsuit:

• - Safety Concerns: It is asserted that ARD-101 posed greater safety risks than Aardvark Therapeutics acknowledged, with unexpected cardiac observations reported during clinical trials.
• - Misleading Statements: The defendants allegedly failed to inform investors about these potential health risks and the implications they had for the drug’s commercial prospects.
• - Impact on Stock Performance: Following revelations about these safety concerns, Aardvark’s stock price suffered substantial declines, dropping over 56% after the announcement of a voluntary pause in its Phase 3 HERO trial due to safety monitoring results. Subsequently, another drop of 32.1% occurred after the FDA imposed a full clinical hold on the drug's investigational new drug application.

The Role of Hagens Berman

Reed Kathrein, the partner leading the investigation at Hagens Berman, underlined the urgency for investors to participate in the class action, stating that they must act before the upcoming deadline of October 13, 2026, if they wish to be designated as Lead Plaintiffs.

The firm is strongly advising affected investors to reach out, ensuring their voices are heard in the pursuit of justice and potential recovery for losses incurred due to Aardvark’s alleged misrepresentation of ARD-101.

What Should Investors Do?

Investors are encouraged to take proactive measures at this stage. If you were a shareholder during the specified class period and have faced financial loss, reach out to Hagens Berman to discuss your legal rights. This lawsuit serves as a reminder of the critical nature of investor vigilance and the expectation of corporate accountability. Aardvark investors who have pertinent non-public information regarding the company are also urged to consider options for whistleblowing, potentially benefiting from the SEC's Whistleblower program, which offers rewards for original information.

Conclusion

The class action against Aardvark Therapeutics is a crucial case that highlights ongoing concerns regarding investor protection in the biopharmaceutical sector. As the deadline approaches, the urgency for investors to assess their involvement increases. This situation underscores a growing need for regulatory frameworks that ensure honesty and integrity within clinical developments and corporate communications, reaffirming the necessity of transparency in maintaining investor confidence.

For more details about the case and its implications, investors can visit Hagens Berman's official page.